6-K - FMS - Equibles

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

For the month of June 2023

Commission file number: 001-32749

FRESENIUS MEDICAL CARE AG & Co. KGaA

(Translation of registrant's name into English)

Else-Kröner Strasse 1

61346 Bad Homburg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

On June 2, 2023, Fresenius Medical Care AG & Co. KGaA (the “Company”) issued its unaudited full year results for the year ending December 31, 2022 and its unaudited quarterly results for the periods ending March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022 under its new global operating model, implemented on January 1, 2023, in which the Company reorganized its business into two global operating segments, Care Delivery and Care Enablement.

The quarterly and full year results contain non-GAAP financial measures. For purposes of Regulation G, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with generally accepted accounting principles. To supplement the Company’s unaudited quarterly and full year 2022 consolidated financial results under the realigned global operating model presented in accordance with International Financial Reporting Standards, or IFRS, we have used non-GAAP financial measures, including (a) EBITDA, or operating income excluding interest, taxes, depreciation and amortization, (b) free cash flow, (c) net leverage ratio (ratio of net debt to adjusted EBITDA) and (d) results presented in constant currency and as adjusted for special items identified in the tables. These non-GAAP measures are provided to enhance the user’s overall understanding of our current financial performance and our prospects for the future. In addition, because we have historically reported certain non-GAAP financial measures in our financial results, we believe the inclusion of these non-IFRS financial measures provides consistency and comparability in our financial reporting to prior periods for which these non-GAAP financial measures were previously reported. These non-GAAP financial measures should not be used as a substitute for or be considered superior to GAAP financial measures. Reconciliation of the non-GAAP financial measures to the most comparable IFRS financial measures are included in the attached Financial Statements. As the reconciliation of amounts stated in Constant Currency is inherent in the disclosure, we believe that a separate reconciliation would not provide any additional benefit.

The attached financial tables shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

EXHIBITS

The following exhibits are being furnished with this Report:

Exhibit 99.1	Complete overview of the first, second, third and fourth quarters<br>2022 and first three, six and nine months as well as full year 2022.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DATE: June 2, 2023

Fresenius Medical Care AG & Co. KGaA,<br><br><br><br>a partnership limited by shares, represented by:<br><br><br><br><br><br><br><br>fresenius medical care management ag, its<br><br><br><br>General Partner
By:	/s/ Helen Giza
Name:	Helen Giza
Title:	Chief Executive Officer, Chair of the Management Board of the General Partner and Acting Chief Financial Officer
By:	/s/ Dr. Katarzyna Mazur-Hofsäß
---	---
Name:	Dr. Katarzyna Mazur-Hofsäß
Title:	CEO Care Enablement and member of the Management Board of the General Partner

Exhibit 99.1

Content:<br>Statement of earnings page 2<br>Segment information page 3<br>Balance sheet page 4<br>Cash flow page 5<br>page 6<br>Key metrics page 7<br>page 8 - 9<br>page 10<br>Outlook 2023 page 11<br>Disclaimer<br>Copyright by Fresenius Medical Care AG & Co. KGaA<br>email: [email protected]<br>phone: +49 6172 609 2525<br>Revenue development by segment<br>Reconciliation results excl. special items<br>This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those<br>described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory<br>reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks<br>and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius<br>Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.<br>Rounding adjustments applied to individual numbers and percentages may result in these figures differing immaterially from their absolute values.<br>Furthermore, totals and subtotals in tables may differ slightly from unrounded figures due to rounding in accordance with commercial rounding<br>conventions.<br>Reconciliation revenue to new segments<br>Fresenius Medical Care AG & Co. KGaA<br>June 2, 2023<br>QUARTERLY OVERVIEW 2022<br>Investor Relations
Statement of earnings<br>in € million, except share data, unaudited Three months<br>ended March 31,<br>Three months<br>ended June 30,<br>Three months<br>ended Sept. 30,<br>Three months<br>ended Dec. 31,<br>Six months<br>ended June 30,<br>Nine months<br>ended Sept. 30,<br>Twelve months<br>ended Dec. 31,<br>2022 2022 2022 2022 2022 2022 2022<br>Total revenue 4,548 4,757 5,096 4,997 9,305 14,401 19,398<br>Operating income 348 341 472 352 688 1,160 1,512<br>Operating income excl. special items and PRF 1 390 284 377 489 675 1,052 1,540<br>Interest income (14) (13) (16) (25) (27) (43) (68)<br>Interest expense 83 85 92 100 168 260 360<br>Interest expense, net 69 72 76 75 141 217 292<br>Income before taxes 279 269 396 277 547 943 1,220<br>Income tax expense 67 63 112 83 130 242 325<br>Net income 212 206 284 194 417 701 895<br>Net income attributable to noncontrolling interests 55 59 54 55 112 166 222<br>Net income attributable to shareholders of<br>FMC AG & Co. KGaA 157 147 230 139 305 535 673<br>Net income attributable to shareholders of<br>FMC AG & Co. KGaA excl. special items and PRF 1 197 116 168 248 313 481 729<br>Operating income 348 341 472 352 688 1,160 1,512<br>Depreciation, amortization and impairment loss 419 422 502 495 842 1,344 1,838<br>EBITDA 767 763 974 847 1,530 2,504 3,350<br>Weighted average number of shares 293,007,109 293,145,413 293,413,449 293,413,449 293,076,643 293,190,145 293,246,430<br>Basic earnings per share €0.54 €0.50 €0.78 €0.47 €1.04 €1.82 €2.30<br>Basic earnings per ADS €0.27 €0.25 €0.39 €0.24 €0.52 €0.91 €1.15<br>In percent of revenue<br>Operating income margin 7.6% 7.2% 9.3% 7.0% 7.4% 8.1% 7.8%<br>Operating income margin excl. special items and PRF 1 8.6% 6.0% 7.4% 9.8% 7.2% 7.3% 7.9%<br>EBITDA margin 16.9% 16.0% 19.1% 16.9% 16.4% 17.4% 17.3%<br>1<br> For a reconciliation of special items, please refer to the table on page 8.<br>Statement of earnings page 2 of 11 June 2, 2023
---
Segment information<br>unaudited Three months<br>ended March 31,<br>Three months<br>ended June 30,<br>Three months<br>ended Sept. 30,<br>Three months<br>ended Dec. 31,<br>Six months<br>ended June 30,<br>Nine months<br>ended Sept. 30,<br>Twelve months<br>ended Dec. 31,<br>2022 2022 2022 2022 2022 2022 2022<br>Total<br>Revenue in € million 4,548 4,757 5,096 4,997 9,305 14,401 19,398<br>Operating income in € million 348 341 472 352 688 1,160 1,512<br>Operating income margin 7.6% 7.2% 9.3% 7.0% 7.4% 8.1% 7.8%<br>Operating income in € million<br>(excluding special items and PRF) 2 390 284 377 489 675 1,052 1,540<br>Operating income margin<br>(excluding special items and PRF) 2 8.6% 6.0% 7.4% 9.8% 7.2% 7.3% 7.9%<br>Days sales outstanding (DSO) 69 69 69 68<br>Employees (headcount) 130,177 130,448 130,295 128,044<br>Care Delivery segment<br>Revenue in € million 3,647 3,822 4,131 3,993 7,469 11,600 15,593<br>Operating income in € million 298 433 500 455 731 1,230 1,686<br>Operating income margin 8.2% 11.3% 12.1% 11.4% 9.8% 10.6% 10.8%<br>Operating income in € million<br>(excluding special items and PRF) 2 310 287 371 509 599 969 1,478<br>Operating income margin<br>(excluding special items and PRF) 2 8.5% 7.5% 9.0% 12.7% 8.0% 8.3% 9.5%<br>Care Enablement segment<br>Revenue in € million 1,267 1,318 1,376 1,392 2,586 3,961 5,353<br>Operating income in € million 69 (11) (26) (61) 59 33 (30)<br>Operating income margin 5.5% -0.8% -1.9% -4.4% 2.3% 0.8% -0.6%<br>Operating income in € million<br>(excluding special items and PRF) 2 96 3 7 (2) 100 107 103<br>Operating income margin<br>(excluding special items and PRF) 2 7.6% 0.2% 0.5% -0.2% 3.8% 2.7% 1.9%<br>Inter-segment eliminations 1<br>Revenue in € million (366) (383) (411) (388) (750) (1,160) (1,548)<br>Operating income in € million (9) 3 5 2 (8) (2) 0<br>Corporate<br>Operating income in € million (10) (84) (7) (44) (94) (101) (144)<br>Operating income in € million<br>(excluding special items and PRF) 2 (7) (9) (6) (20) (16) (22) (41)<br>1<br> The Company transfers products between segments at fair market value. The associated internal revenues and expenses and any remaining internally generated profit or loss for the product<br>transfers are recorded within the operating segments initially, are eliminated upon consolidation and are included within “Inter-segment eliminations”.<br>2<br> For a reconciliation of operating income in € million (excluding special items and PRF) and operating income margin (excluding special items and PRF), please refer to the table on page 8.<br>Segment information page 3 of 11 June 2, 2023
---
Balance sheet<br>in € million, except for net leverage ratio, unaudited March 31, June 30, September 30, December 31,<br> 2022 2022 2022 2022<br>Assets<br>Current assets 8,039 8,105 8,513 8,203<br>Goodwill and intangible assets 16,109 17,144 18,791 17,310<br>Right-of-use assets 4,274 4,450 4,571 4,187<br>Other non-current assets 6,302 6,371 6,531 6,054<br>Total assets 34,724 36,070 38,406 35,754<br>Liabilities and equity<br>Current liabilities 6,377 6,877 6,357 6,467<br>Non-current liabilities 13,808 13,742 15,314 13,838<br>Total equity 14,539 15,451 16,735 15,449<br>Total liabilities and equity 34,724 36,070 38,406 35,754<br>Equity/assets ratio 42% 43% 44% 43%<br>Debt and lease liabilities<br>Short-term debt from unrelated parties 970 1,391 544 665<br>Short-term debt from related parties 145 23 39 4<br>Current portion of long-term debt 59 57 58 694<br>Current portion of lease liabilities from unrelated parties 650 683 710 650<br>Current portion of lease liabilities from related parties 22 22 22 24<br>Long-term debt, less current portion 7,452 7,263 8,068 7,171<br>Lease liabilities from unrelated parties, less current portion 3,951 4,133 4,262 3,875<br>Lease liabilities from related parties, less current portion 94 87 83 130<br>Total debt and lease liabilities 13,343 13,659 13,786 13,213<br>Minus: Cash and cash equivalents (1,173) (1,025) (1,114) (1,274)<br>Total net debt and lease liabilities 12,170 12,634 12,672 11,939<br>Reconciliation of annualized adjusted EBITDA and net<br>leverage ratio to the most directly comparable IFRS<br>financial measures<br>Net income 1,127 1,053 1,004 895<br>Income tax expense 326 313 321 325<br>Interest income (72) (71) (71) (68)<br>Interest expense 345 347 355 360<br>Depreciation and amortization 1,611 1,647 1,693 1,718<br>Adjustments 173 1 260 2 214 3 320 4<br>Annualized adjusted EBITDA 3,510 3,549 3,516 3,550<br>Net leverage ratio 3.5 3.6 3.6 3.4<br>1<br> Acquisitions and divestitures made for the last twelve months with a purchase price above a €50 M threshold as defined in the Syndicated Credit Facility (€9 M),<br>non-cash charges, primarily related to pension expense (€50 M), impairment loss (€43 M), as well as costs related to the FME25 Program (€ 50M) and the impacts<br>related to the War in Ukraine (€21 M).<br>4<br> Acquisitions and divestitures made for the last twelve months with a purchase price above a €50 M threshold as defined in the Syndicated Credit Facility (-€22<br>M), non-cash charges, primarily related to pension expense (€54 M), impairment loss (€120 M) and special items, including costs related to the FME25 Program<br>(€155 M), Net Gain Related to InterWell Health (-€114 M), Humacyte Investment Remeasurement (€103 M), Hyperinflation in Turkiye (€5 M) and the Impacts<br>Related to the War in Ukraine (€19 M).<br>2<br> Acquisitions and divestitures made for the last twelve months with a purchase price above a €50 M threshold as defined in the Syndicated Credit Facility (€4<br>M), non-cash charges, primarily related to pension expense (€51 M), impairment loss (€35 M) and special items, including costs related to the FME25 Program (€<br>63 M), Humacyte Investment Remeasurement (€78 M), Hyperinflation in Turkiye (€6 M) and the Impacts Related to the War in Ukraine (€23 M).<br>3<br> Acquisitions and divestitures made for the last twelve months with a purchase price above a €50 M threshold as defined in the Syndicated Credit Facility (-€27<br>M), non-cash charges, primarily related to pension expense (€52 M), impairment loss (€88 M) and special items, including costs related to the FME25 Program<br>(€106 M), Net Gain Related to InterWell Health (-€113 M), Humacyte Investment Remeasurement (€79 M), Hyperinflation in Turkiye (€6 M) and the Impacts<br>Related to the War in Ukraine (€23 M).<br>Balance sheet page 4 of 11 June 2, 2023
---
Cash flow statement<br>in € million, unaudited Three months<br>ended March 31,<br>Three months<br>ended June 30,<br>Three months<br>ended Sept. 30,<br>Three months<br>ended Dec. 31,<br>Six months<br>ended Sept. 30,<br>Nine months<br>ended Sept. 30,<br>Twelve months<br>ended Dec. 31,<br>2022 2022 2022 2022 2022 2022 2022<br>Operating activities<br>Net income 212 206 284 194 417 701 895<br>Depreciation, amortization and impairment loss 419 422 502 495 842 1,344 1,838<br>Change in working capital and other non-cash items (472) 123 (128) (89) (349) (477) (566)<br>Net cash provided by (used in) operating activities 159 751 658 600 910 1,568 2,167<br>In percent of revenue 3.5% 15.8% 12.9% 12.0% 9.8% 10.9% 11.2%<br>Investing activities<br>Purchases of property, plant and equipment and capitalized development<br>costs (162) (172) (160) (229) (334) (495) (724)<br>Proceeds from sale of property, plant and equipment 2 3 3 27 5 9 37<br>Capital expenditures, net (160) (169) (157) (202) (329) (486) (687)<br>Free cash flow (1) 582 501 398 581 1,082 1,480<br>In percent of revenue 0.0% 12.2% 9.8% 8.0% 6.2% 7.5% 7.6%<br>Acquisitions and investments, net of cash acquired, and purchases of<br>intangible assets (36) (24) 21 (19) (61) (40) (59)<br>Investments in debt securities (43) (43) (6) (14) (86) (92) (106)<br>Proceeds from divestitures 14 26 16 4 40 56 60<br>Proceeds from sale of debt securities 13 13 25 6 27 52 58<br>Free cash flow after investing activities (53) 554 557 375 501 1,058 1,433<br>Cash flow page 5 of 11 June 2, 2023
---
in € million, unaudited<br>Three months<br>ended March 31,<br>Three months<br>ended June 30,<br>Three months<br>ended Sept. 30,<br>Three months<br>ended Dec. 31,<br>Six months<br>ended June 30,<br>Nine months<br>ended Sept. 30,<br>Twelve months<br>ended Dec. 31,<br>2022 2022 2022 2022 2022 2022 2022<br>Total revenue 4,548 4,757 5,096 4,997 9,305 14,401 19,398<br>Care Delivery segment 3,647 3,822 4,131 3,993 7,469 11,600 15,593<br>Thereof: U.S. 2,930 3,066 3,318 3,261 5,996 9,314 12,575<br>Thereof: International 717 756 813 732 1,473 2,286 3,018<br>Care Enablement segment 1,267 1,318 1,376 1,392 2,586 3,961 5,353<br>Inter-segment eliminations (366) (383) (411) (388) (750) (1,160) (1,548)<br>Revenue development by segment<br>Revenue development by segment page 6 of 11 June 2, 2023
---
unaudited<br>Clinics Net change<br>in clinics 1 Patients Treatments<br>Three months ended March 31, 2022<br>Total 4,153 (18) 343,493 12,858,103<br>Thereof: U.S. 2,680 (3) 204,837 7,691,660<br>Thereof: International 1,473 (15) 138,656 5,166,443<br>Six months ended June 30, 2022<br>Total 4,163 (8) 345,687 25,932,144<br>Thereof: U.S. 2,682 (1) 206,766 15,544,134<br>Thereof: International 1,481 (7) 138,921 10,388,010<br>Nine months ended September 30, 2022<br>Total 4,153 (18) 344,593 39,152,144<br>Thereof: U.S. 2,687 4 205,985 23,491,632<br>Thereof: International 1,466 (22) 138,608 15,660,512<br>Twelve months ended December 31, 2022<br>Total 4,116 (55) 344,687 52,310,131<br>Thereof: U.S. 2,671 (12) 206,033 31,361,555<br>Thereof: International 1,445 (43) 138,654 20,948,576<br>Key metrics Care Delivery segment<br>1<br> Net change in clinics (acquired, de novo, combined, closed and sold) in comparison to December 31, 2021.<br>Key metrics page 7 of 11 June 2, 2023
---
in € million, except share data, unaudited Results 2022 FME25 Program<br>Net Gain<br>Related to<br>InterWell<br>Health1<br>Humacyte<br>Investment<br>Remeasurement Ukraine War2<br>Hyperinflation<br>in Turkiye<br>Provider Relief<br>Funding (PRF)<br>Sum of Special<br>items and PRF<br>Results 2022<br>excl. special<br>items<br>and PRF<br>Three months ended March 31,<br>Total revenue 4,548 — 4,548<br>EBITDA 767 28 — 3 21 — (16) 36 803<br>Total operating income 348 33 — 3 22 — (16) 42 390<br>Care Delivery segment 298 20 — — 8 — (16) 12 310<br>Care Enablement segment 69 13 — — 14 — — 27 96<br>Inter-segment eliminations (9) — — — — — — — (9)<br>Corporate (10) — — 3 — — — 3 (7)<br>Interest expense, net 69 — 69<br> —<br>Income tax expense 67 9 — 0 3 — (4) 8 75<br>Net income attributable to noncontrolling<br>interests 55 — — — — — (6) (6) 49<br>Net income3 157 24 — 3 19 — (6) 40 197<br>Basic earnings per share €0.54 €0.08 — €0.01 €0.06 — €(0.02) €0.13 €0.67<br>Three months ended June 30,<br>Total revenue 4,757 — 4,757<br>EBITDA 763 21 — 75 2 6 (161) (57) 706<br>Total operating income 341 21 — 75 2 6 (161) (57) 284<br>Care Delivery segment 433 13 — — 2 0 (161) (146) 287<br>Care Enablement segment (11) 8 — — 0 6 — 14 3<br>Inter-segment eliminations 3 — — — — — — — 3<br>Corporate (84) — — 75 — — — 75 (9)<br>Interest expense, net 72 — 72<br>Income tax expense 63 6 — 20 — — (42) (16) 47<br>Net income attributable to noncontrolling<br>interests 59 — — — — — (10) (10) 49<br>Net income3 147 15 — 55 2 6 (109) (31) 116<br>Basic earnings per share €0.50 €0.05 — €0.19 €0.01 €0.02 €(0.38) €(0.11) €0.39<br>Three months ended Sept. 30,<br>Total revenue 5,096 — 5,096<br>EBITDA 974 52 (113) 1 0 0 (93) (153) 821<br>Total operating income 472 53 (56) 1 0 0 (93) (95) 377<br>Care Delivery segment 500 20 (56) — 1 (1) (93) (129) 371<br>Care Enablement segment (26) 33 — — (1) 1 — 33 7<br>Inter-segment eliminations 5 — — — — — — — 5<br>Corporate (7) — — 1 — — — 1 (6)<br>Interest expense, net 76 — 76<br>Income tax expense 112 15 (18) 0 0 — (25) (28) 84<br>Net income attributable to noncontrolling<br>interests 54 — — — — — (5) (5) 49<br>Net income3 230 38 (38) 1 0 0 (63) (62) 168<br>Basic earnings per share €0.78 €0.13 €(0.13) €0.01 €0.00 €0.00 €(0.22) €(0.21) €0.57<br>Three months ended Dec. 31,<br>Total revenue 4,997 — 4,997<br>EBITDA 847 53 (1) 24 (3) (1) (6) 66 913<br>Total operating income 352 95 0 24 25 (1) (6) 137 489<br>Care Delivery segment 455 63 0 — (2) (1) (6) 54 509<br>Care Enablement segment (61) 32 — — 27 0 — 59 (2)<br>Inter-segment eliminations 2 — — — — — — — 2<br>Corporate (44) — — 24 — — — 24 (20)<br>Interest expense, net 75 — 75<br>Income tax expense 83 25 (1) 6 (1) — (1) 28 111<br>Net income attributable to noncontrolling<br>interests 55 — — — — — 0 0 55<br>Net income3 139 70 1 18 26 (1) (5) 109 248<br>Basic earnings per share €0.47 €0.24 €0.00 €0.06 €0.09 €0.00 €(0.01) €0.38 €0.85<br>Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures for comparability with the Company´s outlook<br>Special items<br>Reconciliation results excl. special items page 8 of 11 June 2, 2023
---
in € million, except share data, unaudited Results 2022 FME25 Program<br>Net Gain<br>Related to<br>InterWell<br>Health1<br>Humacyte<br>Investment<br>Remeasurement Ukraine War2<br>Hyperinflation<br>in Turkiye<br>Provider Relief<br>Funding (PRF)<br>Sum of Special<br>items and PRF<br>Results 2022<br>excl. special<br>items<br>and PRF<br>Six months ended June 30,<br>Total revenue 9,305 — 9,305<br>EBITDA 1,530 49 — 78 23 6 (177) (21) 1,509<br>Total operating income 688 57 — 78 23 6 (177) (13) 675<br>Care Delivery segment 731 35 — — 10 0 (177) (132) 599<br>Care Enablement segment 59 22 — — 13 6 — 41 100<br>Inter-segment eliminations (8) — — — — — — — (8)<br>Corporate (94) — — 78 — — — 78 (16)<br>Interest expense, net 141 — 141<br>Income tax expense 130 17 — 21 3 — (48) (7) 123<br>Net income attributable to noncontrolling<br>interests 112 — — — — — (14) (14) 98<br>Net income3 305 40 — 57 20 6 (115) 8 313<br>Basic earnings per share €1.04 €0.14 — €0.19 €0.07 €0.02 €(0.39) €0.03 €1.07<br>Nine months ended Sept. 30,<br>Total revenue 14,401 — 14,401<br>EBITDA 2,504 101 (113) 79 23 6 (270) (174) 2,330<br>Total operating income 1,160 109 (56) 79 24 6 (270) (108) 1,052<br>Care Delivery segment 1,230 55 (56) — 11 (1) (270) (261) 969<br>Care Enablement segment 33 54 — — 13 7 — 74 107<br>Inter-segment eliminations (2) — — — — — — — (2)<br>Corporate (101) — — 79 — — — 79 (22)<br>Interest expense, net 217 — 217<br>Income tax expense 242 31 (18) 21 3 — (72) (35) 207<br>Net income attributable to noncontrolling<br>interests 166 — — — — — (19) (19) 147<br>Net income3 535 78 (38) 58 21 6 (179) (54) 481<br>Basic earnings per share €1.82 €0.27 €(0.13) €0.20 €0.07 €0.02 €(0.61) €(0.18) €1.64<br>Twelve months ended December 31,<br>Total revenue 19,398 — 19,398<br>EBITDA 3,350 155 (114) 103 19 5 (277) (109) 3,241<br>Total operating income 1,512 204 (56) 103 49 5 (277) 28 1,540<br>Care Delivery segment 1,686 118 (56) — 9 (2) (277) (208) 1,478<br>Care Enablement segment (30) 86 — — 40 7 — 133 103<br>Inter-segment eliminations 0 — — — — — — — 0<br>Corporate (144) — — 103 — — — 103 (41)<br>Interest expense, net 292 — 292<br>Income tax expense 325 55 (19) 27 2 — (73) (8) 317<br>Net income attributable to noncontrolling<br>interests 222 (20) (20) 202<br>Net income3 673 149 (37) 76 47 5 (184) 56 729<br>Basic earnings per share €2.30 €0.50 €(0.13) €0.26 €0.16 €0.02 €(0.63) €0.18 €2.48<br>2<br> Bad debt expense in Russia and Ukraine and accruals for certain risks associated with allowances on inventories related to the Ukraine War.<br>1<br> Remeasurement gain of the investment, prior to the transaction, in InterWell Health LLC, the impairment of certain long-lived assets belonging to Acumen Physician Solutions, LLC which was transferred<br>to InterWell Health as part of the transaction and certain transaction-related costs.<br>3<br> Attributable to shareholders of FMC AG & Co. KGaA<br>Special items<br>Reconciliation results excl. special items page 9 of 11 June 2, 2023
---
in € million, unaudited<br>Care<br>Delivery<br>Care<br>Enablement Total Segment<br>Inter-segment<br>eliminations Total<br>Three months ended March 31, 2022<br>Revenue from health care services 3,607 — 3,607 — 3,607<br>Revenue from health care products 40 901 941 — 941<br>Revenue from external customers 3,647 901 4,548 — 4,548<br>Inter-segment revenue 366 366 (366) —<br>Revenue 3,647 1,267 4,914 (366) 4,548<br>Three months ended June 30, 2022<br>Revenue from health care services 3,782 — 3,782 — 3,782<br>Revenue from health care products 40 935 975 — 975<br>Revenue from external customers 3,822 935 4,757 — 4,757<br>Inter-segment revenue 383 383 (383) —<br>Revenue 3,822 1,318 5,140 (383) 4,757<br>Three months ended September 30, 2022<br>Revenue from health care services 4,082 — 4,082 — 4,082<br>Revenue from health care products 49 965 1,014 — 1,014<br>Revenue from external customers 4,131 965 5,096 — 5,096<br>Inter-segment revenue 411 411 (411) —<br>Revenue 4,131 1,376 5,507 (411) 5,096<br>Three months ended December 31, 2022<br>Revenue from health care services 3,947 — 3,947 — 3,947<br>Revenue from health care products 46 1,004 1,050 — 1,050<br>Revenue from external customers 3,993 1,004 4,997 — 4,997<br>Inter-segment revenue 388 388 (388) —<br>Revenue 3,993 1,392 5,385 (388) 4,997<br>Six months ended June 30, 2022<br>Revenue from health care services 7,389 — 7,389 — 7,389<br>Revenue from health care products 80 1,836 1,916 — 1,916<br>Revenue from external customers 7,469 1,836 9,305 — 9,305<br>Inter-segment revenue 750 750 (750) —<br>Revenue 7,469 2,586 10,055 (750) 9,305<br>Nine months ended September 30, 2022<br>Revenue from health care services 11,471 — 11,471 — 11,471<br>Revenue from health care products 129 2,801 2,930 — 2,930<br>Revenue from external customers 11,600 2,801 14,401 — 14,401<br>Inter-segment revenue 1,160 1,160 (1,160) —<br>Revenue 11,600 3,961 15,561 (1,160) 14,401<br>Twelve months ended December 31, 2022<br>Revenue from health care services 15,418 — 15,418 — 15,418<br>Revenue from health care products 175 3,805 3,980 — 3,980<br>Revenue from external customers 15,593 3,805 19,398 — 19,398<br>Inter-segment revenue 1,548 1,548 (1,548) —<br>Revenue 15,593 5,353 20,946 (1,548) 19,398<br> Reconciliation of Health Care Product and Health Care Service revenue to new segments<br>Reconciliation revenue to new segments page 10 of 11 June 2, 2023
---
Outlook 2023<br>Spalte1 Results 2022<br>Outlook 2023<br>(at Constant Currency)<br>Revenue1 €19,398 M low to mid-single digit percentage rate growth<br>Operating income1 €1,540 M flat to high-single digit percentage rate decline<br>1 Outlook 2023 is based on the assumptions outlined in the earnings release for the fourth quarter and full year of 2022 and excludes special items. Special items<br>include further costs related to the FME25 program, Legal Structure Conversion Costs, Strategic Divestment Program and other effects that are unusual in nature<br>and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance. The growth rates are based on the results 2022 excluding the<br>costs related to the FME25 program (€204 M for operating income), Net Gain Related to InterWell Health (-€56 M for operating income), Humacyte Investment<br>Remeasurement (€103 M for operating income), Hyperinflation in Turkiye (€5 M for operating income) and the Impacts Related to the War in Ukraine (€49 M for<br>operating income). Additionally, the results 2022 were adjusted for the Provider Relief Funding (-€277 M for operating income).<br>Outlook 2023 page 11 of 11 June 2, 2023
---